vs
礼来(RNA)与RIVERVIEW BANCORP INC(RVSB)财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是礼来的1.1倍($14.0M vs $12.5M),RIVERVIEW BANCORP INC净利率更高(9.8% vs -1398.3%,领先1408.1%),礼来同比增速更快(434.0% vs 10.4%),RIVERVIEW BANCORP INC自由现金流更多($-736.0K vs $-156.9M),过去两年礼来的营收复合增速更高(138.5% vs 24.6%)
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业,在18个国家设有办事处,产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立,品牌名即取自创始人姓名。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司,主营个人与商业银行业务,服务覆盖太平洋西北地区,提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品,服务零售客户与本地企业群体。
RNA vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.1倍
$12.5M
营收增速更快
RNA
高出423.7%
10.4%
净利率更高
RVSB
高出1408.1%
-1398.3%
自由现金流更多
RVSB
多$156.1M
$-156.9M
两年增速更快
RNA
近两年复合增速
24.6%
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | ||
|---|---|---|
| 营收 | $12.5M | $14.0M |
| 净利润 | $-174.4M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -1513.5% | 12.4% |
| 净利率 | -1398.3% | 9.8% |
| 营收同比 | 434.0% | 10.4% |
| 净利润同比 | -117.0% | 11.8% |
| 每股收益(稀释后) | $-1.27 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
RNA
RVSB
| Q4 25 | — | $14.0M | ||
| Q3 25 | $12.5M | $13.6M | ||
| Q2 25 | $3.8M | $13.3M | ||
| Q1 25 | $1.6M | $12.9M | ||
| Q4 24 | $3.0M | $12.7M | ||
| Q3 24 | $2.3M | $12.8M | ||
| Q2 24 | $2.0M | $12.2M | ||
| Q1 24 | $3.5M | $9.0M |
净利润
RNA
RVSB
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-174.4M | $1.1M | ||
| Q2 25 | $-157.3M | $1.2M | ||
| Q1 25 | $-115.8M | $1.1M | ||
| Q4 24 | $-102.3M | $1.2M | ||
| Q3 24 | $-80.4M | $1.6M | ||
| Q2 24 | $-70.8M | $966.0K | ||
| Q1 24 | $-68.9M | $-3.0M |
营业利润率
RNA
RVSB
| Q4 25 | — | 12.4% | ||
| Q3 25 | -1513.5% | 10.2% | ||
| Q2 25 | -4448.7% | 11.7% | ||
| Q1 25 | -8360.9% | 11.3% | ||
| Q4 24 | -4069.6% | 12.4% | ||
| Q3 24 | -4200.9% | 15.5% | ||
| Q2 24 | -4040.4% | 10.0% | ||
| Q1 24 | -2178.6% | -47.5% |
净利率
RNA
RVSB
| Q4 25 | — | 9.8% | ||
| Q3 25 | -1398.3% | 8.1% | ||
| Q2 25 | -4089.3% | 9.2% | ||
| Q1 25 | -7360.0% | 8.9% | ||
| Q4 24 | -3439.5% | 9.7% | ||
| Q3 24 | -3441.7% | 12.2% | ||
| Q2 24 | -3461.8% | 7.9% | ||
| Q1 24 | -1943.4% | -34.7% |
每股收益(稀释后)
RNA
RVSB
| Q4 25 | — | $0.07 | ||
| Q3 25 | $-1.27 | $0.05 | ||
| Q2 25 | $-1.21 | $0.06 | ||
| Q1 25 | $-0.90 | $0.05 | ||
| Q4 24 | $-0.80 | $0.06 | ||
| Q3 24 | $-0.65 | $0.07 | ||
| Q2 24 | $-0.65 | $0.05 | ||
| Q1 24 | $-0.79 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $350.2M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $164.2M |
| 总资产 | $2.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
RNA
RVSB
| Q4 25 | — | $28.6M | ||
| Q3 25 | $350.2M | $32.8M | ||
| Q2 25 | $243.9M | $34.2M | ||
| Q1 25 | $254.2M | $29.4M | ||
| Q4 24 | $219.9M | $25.3M | ||
| Q3 24 | $370.2M | $31.0M | ||
| Q2 24 | $575.8M | $27.8M | ||
| Q1 24 | $471.4M | $23.6M |
股东权益
RNA
RVSB
| Q4 25 | — | $164.2M | ||
| Q3 25 | $1.9B | $163.5M | ||
| Q2 25 | $1.2B | $162.0M | ||
| Q1 25 | $1.3B | $160.0M | ||
| Q4 24 | $1.4B | $158.3M | ||
| Q3 24 | $1.5B | $160.8M | ||
| Q2 24 | $1.2B | $155.9M | ||
| Q1 24 | $830.9M | $155.6M |
总资产
RNA
RVSB
| Q4 25 | — | $1.5B | ||
| Q3 25 | $2.1B | $1.5B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.5B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.3B | $1.5B | ||
| Q1 24 | $951.5M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-156.2M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-156.9M | $-736.0K |
| 自由现金流率自由现金流/营收 | -1257.6% | -5.2% |
| 资本支出强度资本支出/营收 | 5.7% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-592.3M | $20.4M |
8季度趋势,按日历期对齐
经营现金流
RNA
RVSB
| Q4 25 | — | $-506.0K | ||
| Q3 25 | $-156.2M | $16.8M | ||
| Q2 25 | $-199.7M | $-697.0K | ||
| Q1 25 | $-124.8M | $8.3M | ||
| Q4 24 | $-99.9M | $2.2M | ||
| Q3 24 | $-65.6M | $764.0K | ||
| Q2 24 | $-65.0M | $5.4M | ||
| Q1 24 | $-70.4M | $12.8M |
自由现金流
RNA
RVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | $-156.9M | $16.4M | ||
| Q2 25 | $-203.0M | $-773.0K | ||
| Q1 25 | $-128.6M | $5.6M | ||
| Q4 24 | $-103.8M | $1.9M | ||
| Q3 24 | $-67.3M | $-1.4M | ||
| Q2 24 | $-65.5M | $5.3M | ||
| Q1 24 | $-71.3M | $7.1M |
自由现金流率
RNA
RVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | -1257.6% | 120.1% | ||
| Q2 25 | -5277.1% | -5.8% | ||
| Q1 25 | -8174.3% | 43.1% | ||
| Q4 24 | -3491.0% | 15.0% | ||
| Q3 24 | -2881.8% | -11.3% | ||
| Q2 24 | -3204.6% | 43.7% | ||
| Q1 24 | -2012.3% | 79.0% |
资本支出强度
RNA
RVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | 5.7% | 2.9% | ||
| Q2 25 | 86.9% | 0.6% | ||
| Q1 25 | 238.6% | 21.0% | ||
| Q4 24 | 131.7% | 2.4% | ||
| Q3 24 | 72.9% | 17.3% | ||
| Q2 24 | 26.0% | 0.9% | ||
| Q1 24 | 25.8% | 62.0% |
现金转化率
RNA
RVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图